Corxel and LENZ share positive results from Phase III China trial

Corxel Pharmaceuticals and LENZ Therapeutics (Nasdaq: LENZ) have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100.

The firms are developing the product for the treatment of presbyopia, an age-related condition where the eye’s lens gradually loses flexibility, making it difficult to focus on close objects.

Corxel holds rights to the drug in China, where the condition impacts an estimated 400 million people. LENZ is advancing regulatory approval of LNZ100 in the USA, with a New Drug Application recently accepted by the US Food and Drug Administration.